A Chinese study is the first to identify fibroblast activation protein (Fap) as an osteogenic suppressor that could be targeted to prevent osteoporosis and has shown that osteolectin, a bone glycoprotein that binds calcium, is an endogenous Fap inhibitor promoting bone mineralization.
HONG KONG – Belgium-based Bone Therapeutics SA has inked development and commercialization deals for its bone cell therapy platform in Chinese and Southeast Asian markets.
HONG KONG – Belgium-based Bone Therapeutics SA has inked development and commercialization deals for its bone cell therapy platform in Chinese and Southeast Asian markets.
Scribe Therapeutics Inc., another CRISPR-based genome editing firm out of the Jennifer Doudna stable, launched with $20 million in series A funding and a deal with Biogen Inc. in amyotrophic lateral sclerosis (ALS), which brings in another $15 million up front and up to $400 million in development and commercial milestones.
RSS
